Benlysta (belimumab) / GSK - LARVOL DELTA

Daratumumab and belimumab for patients with neutralising anti-interferon-γ autoantibodies mediated adult-onset immunodeficiency: a case series (ESCMID Global 2026) - No abstract available

Clinical • IFNG

FROM VISION TO REALITY: EVALUATING SAFETY OF THE FIRST IN HOUSE IMPLEMENTED CD19 CAR-T IN UNITED ARAB EMIRATES FOR SLE PATIENTS (EBMT 2026) - "Biologic B-cell–targeted therapies such as rituximab and BAFF (BlyS) inhibitor therapy such as belimumab have advanced disease control by reducing autoantibody production and modulating immune activation...After rigorous quality control—including sterility, immunophenotyping, and vector copy number—patients received lymphodepletion with fludarabine (25 mg/m² for three days) and cyclophosphamide (1,000 mg/m² for one day)...Treatment demonstrated a favorable safety profile: two patients developed grade <3 cytokine release syndrome resolving after a single tocilizumab dose, and no grade ≥4 CRS or ICANS occurred...Two patients experienced CMV reactivation, managed successfully with oral valganciclovir. UAE's locally produced CD19 CAR-T therapy for SLE shows feasibility, safety, and powerful efficacy, inspiring a bold new era of accessible cellular treatments transforming autoimmune care worldwide for patients."

Clinical • IO biomarker • Autoimmune Hemolytic Anemia • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hemophilia • Hemophilia A • Immune Thrombocytopenic Purpura • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rare Diseases • Rheumatology • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Belimumab induces early and sustained resolution of lupus arthritis. (PubMed, Ann Rheum Dis) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Rheumatology

Response to correspondence on 'Anifrolumab in childhood-onset systemic lupus erythematosus: a promising option after belimumab failure' by Argüelles Balas et al. (PubMed, Ann Rheum Dis) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Correspondence on 'Anifrolumab in childhood-onset systemic lupus erythematosus: a promising option after belimumab failure' by Argüelles Balas et al. (PubMed, Ann Rheum Dis) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Does adding concomitant immunosuppressive therapy to belimumab provide additional benefits in SLE? Results From the BEL-Spain Registry. (PubMed, Rheumatology (Oxford)) - "In this real-world cohort, BEL monotherapy achieved similar outcomes to combination therapy with IS in selected SLE patients. Prospective studies are needed to confirm these findings and define optimal treatment strategies."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Case Report: Telitacicept exposure in early pregnancy in a patient with SLE delivering an infant without any physical defect. (PubMed, Front Med (Lausanne)) - "The use of biologics is not recommended during pregnancy in SLE patients; belimumab or rituximab may be considered selectively only during lactation...During gestation, she was maintained on oral glucocorticoids, hydroxychloroquine, and tacrolimus. On 23 June 2025, at 32 weeks of gestation, she underwent a cesarean section due to "intrauterine growth restriction and preeclampsia" and delivered a male infant without any physical defects. This case suggests that exposure to telitacicept in the early stage of pregnancy did not result in structural defects in this case."

Journal • Gynecology • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

What's New in Cutaneous Lupus Erythematosus: Guidelines, Biologics, and Beyond. (PubMed, J Clin Aesthet Dermatol) - "Ongoing therapeutic innovation, guided by mechanistic insights and strengthened by the development of standardized outcome measures, is transforming the CLE landscape and advancing the goal of precision-based, durable disease control."

Journal • Review • CNS Disorders • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

Dichotomous pathogenesis drives therapeutic choice: A case report and review of literature differentiating glucocorticoid-induced from disease activity-associated central serous chorioretinopathy in lupus nephritis. (PubMed, Lupus) - "This study aims to propose a clinically actionable framework for differentiating these entities and guide trigger-specific treatment selection.MethodsWe present a novel case of glucocorticoid (GC)-induced CSC successfully treated with a GC-free belimumab-tacrolimus regimen...This distinction informs opposing therapeutic strategies: standard GC-based immunosuppression is appropriate for the former, while prompt initiation of GC-sparing therapy is imperative for the latter. This proposed framework offers a path to resolve the longstanding therapeutic paradox in this complex clinical scenario."

Journal • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Ophthalmology • Retinal Disorders • Systemic Lupus Erythematosus

Parallel improvement of chorea and antiphospholipid autoimmunity during combination therapy with hydroxychloroquine, belimumab and glucocorticoids in systemic lupus erythematosus. (PubMed, Mod Rheumatol Case Rep) - "Treatment options include anticonvulsants, dopamine antagonists, antiplatelets, anticoagulants, and immunosuppressants such as cyclophosphamide; however, no specific treatment has been established. A systematic literature review revealed no previously reported cases of chorea associated with SLE treated with a combination of hydroxychloroquine and belimumab. Our case suggests this combination therapy may have a role in maintaining remission and modulating antiphospholipid autoimmunity of SLE-associated chorea."

Journal • Immunology • Inflammatory Arthritis • Lupus • Movement Disorders • Systemic Lupus Erythematosus

Molecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response. (PubMed, J Autoimmun) - "RNA sequencing was performed in blood samples from 21 SLE patients who failed to achieve Lupus Low Disease Activity State after six months of treatment with cyclophosphamide (n = 9), rituximab (n = 5), or belimumab (n = 7). Transcriptome reversal analysis suggested that patients of the T cell-dominant endotype may be more responsive to CD19 CAR-T cell therapy. In summary, distinct molecular endotypes underlie insufficient response to therapy in SLE, providing a framework for personalized treatment strategies and improved clinical trial design."

IO biomarker • Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IL17A • IL6

Telitacicept versus belimumab in proliferative lupus nephritis. (PubMed, Front Immunol) - "In this preliminary study, telitacicept appears to induce earlier renal and immunologic remission than belimumab, along with a potential reduction in the need for glucocorticoids and immunosuppressants. Further validation in larger studies is needed."

Clinical • Journal • Retrospective data • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

BXSB.Yaa: A Translational Model of Toll-Like Receptor 7-Type I Interferon-Driven Systemic Lupus Erythematosus. (PubMed, Immunology) - "Despite recent approvals of belimumab and anifrolumab, durable, steroid-sparing remission in systemic lupus erythematosus (SLE) remains uncommon, underscoring ongoing therapeutic needs. We synthesise insights from BXSB.Yaa studies, including those that informed FDA-approved biologics, and discuss implications for next-generation precision therapies. Collectively, we advocate for BXSB.Yaa as an essential pre-clinical platform among complementary models to accelerate mechanism-based drug development and enable stratified translation in SLE research."

Journal • Review • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IFNG • TLR5 • TLR7

A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus. (clinicaltrials.gov) - P=N/A | N=180 | Not yet recruiting | Sponsor: Yipeng Liu | Trial completion date: Jun 2028 ➔ Sep 2029 | Initiation date: Aug 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2027 ➔ Sep 2029

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data. (clinicaltrials.gov) - P=N/A | N=180 | Active, not recruiting | Sponsor: Yipeng Liu | Trial completion date: Aug 2025 ➔ Mar 2026 | Initiation date: May 2025 ➔ Nov 2025 | Trial primary completion date: Jun 2025 ➔ Mar 2026

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study. (clinicaltrials.gov) - P=N/A | N=56 | Completed | Sponsor: Yipeng Liu | Active, not recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Dec 2025 | Initiation date: May 2025 ➔ Oct 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China. (PubMed, Front Public Health) - "Telitacicept is more cost-saving than belimumab (Dominant). Under current pricing, treatment settings and efficacy data in China, telitacicept demonstrates superior cost-effectiveness compared with belimumab for long-term SLE management by reducing medication costs while delivering additional health benefits."

HEOR • Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Pemphigus Vulgaris Successfully Treated with Belimumab: A Case Report. (PubMed, Indian J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pemphigus Vulgaris

Pharmacovigilance Analysis of Belimumab in Children Based on Clinical Practice Combined with FAERS Database (ChiCTR) - P=N/A | N=11 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University

New trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

New biological agents in systemic lupus erythematosus. (PubMed, Expert Opin Biol Ther) - "The approval in 2011 of belimumab, the first biologic approved for systemic lupus erythematosus (SLE), paved the way for testing additional biologic agents to expand treatment options for SLE...The treatment approach for SLE is shifting toward a balanced and targeted immunosuppression tailored to key drivers of SLE pathophysiology and diverse phenotypes. Given the number of agents already or soon-to-be approved, the appropriate therapy for a given patient must be a shared patient-physician decision."

Journal • Review • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • CD20 • CD40LG

BENLYSTA® Special Drug Use Investigation (clinicaltrials.gov) - P=N/A | N=1514 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed | N=600 ➔ 1514 | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Jun 2025 ➔ Sep 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A multicenter prospective cohort study comparing the efficacy and safety of telitacicept and belimumab in the treatment of systemic lupus erythematosus. (ChiCTR) - P=N/A | N=180 | Not yet recruiting | Sponsor: Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital

New trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry. (PubMed, Lupus Sci Med) - "BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice."

Journal • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Effect of Belimumab on the Cutaneous Manifestations of Patients With Lupus Erythematosus. (PubMed, Int J Dermatol) - "This retrospective analysis demonstrated that belimumab has long-term benefits for cutaneous manifestations of patients with lupus erythematosus. However, prospective studies in larger patient populations are needed to confirm the findings."

Journal • Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Pain • Respiratory Diseases • Systemic Lupus Erythematosus

Efficacy of belimumab on extra-renal lupus in patients with lupus nephritis and end-stage renal disease. (PubMed, Front Med (Lausanne)) - "The primary endpoints included changes in extra-renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, adjustments in prednisone dosages, and the incidence of infection episodes during belimumab therapy. Belimumab appears to be a promising therapeutic option for ESRD-LN patients, effectively controlling extra-renal disease activity, reducing glucocorticoid use, and demonstrating a favorable safety profile. Further research is required to optimize dosing strategies and to validate the long-term efficacy and safety of belimumab in this high-risk population."

Journal • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus